Resection for thoracic metastases from sarcoma
- PMID: 22229212
Resection for thoracic metastases from sarcoma
Abstract
Sarcoma metastasizes to the lungs in 20% to 40% of patients and in most cases does not involve any other organ. Systemic chemotherapy is of unproven benefit for stage IV sarcoma. Retrospective studies have shown 5-year survival rates of 21% to 38% with wedge resection of metastatic pulmonary nodules, and up to 30% to 40% of patients survive an additional 5 years with repeated metastasectomy. In this article, we provide an extensive review of patient selection criteria and surgical approaches, as well as of controversies regarding resection for metastatic sarcoma.
Comment in
-
Resection of pulmonary metastases: a mechanical solution for a biological problem.Oncology (Williston Park). 2011 Nov 15;25(12):1206-7. Oncology (Williston Park). 2011. PMID: 22229213 No abstract available.
-
Comments regarding lung metastasis surgery for sarcoma.Oncology (Williston Park). 2011 Nov 15;25(12):1210-1. Oncology (Williston Park). 2011. PMID: 22229214 No abstract available.
-
Thoracic metastases from sarcoma: a commentary.Oncology (Williston Park). 2011 Nov 15;25(12):1211-2. Oncology (Williston Park). 2011. PMID: 22229215 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical